Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Intranasal Administration of Active Agents to the Central Nervous System

a technology of active agents and central nervous system, which is applied in the direction of immunological disorders, antibody medical ingredients, metabolism disorders, etc., can solve the problems of difficult delivery of drugs to the central nervous system (cns), poor access to cns targets from the peripheral circulation, and little evidence of protein macromolecule delivery to the cns via intranasal pathways, etc., to achieve the effect of improving intranasal administration

Inactive Publication Date: 2009-05-28
BENTZ JOHANNA +2
View PDF21 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]An aspect of the invention is a pharmaceutical composition comprising a catalytically active peptide chain or a peptide chain comprising an antibody Fc or Fab fragment; and a permeation enhancer in a concentration sufficient to enhance intranasal administration of the catalytically active peptide chain or peptide chain comprising an antibody Fc or Fab fragment to the central nervous system of an animal.

Problems solved by technology

Delivery of drugs to the central nervous system (CNS) remains a challenge, despite recent advances in drug delivery and knowledge of mechanisms of delivery of drugs to the brain.
For example, CNS targets are poorly accessible from the peripheral circulation due to the blood-brain barrier (BBB), which provides an efficient barrier for the diffusion of most, especially polar, drugs into the brain from the circulating blood.
Although intranasal delivery to the CNS has been demonstrated for a number of small molecules and some peptides and smaller proteins, there is little evidence demonstrating the delivery of protein macromolecules to the CNS via intranasal pathways, presumably due to the larger size and varying physico-chemical properties unique to each macromolecule or class of macromolecules, that may hinder direct nose-to-brain delivery.
In published delivery studies to date, intranasal delivery efficiency to the CNS has been very low and the delivery of large globular macromolecules, such as antibodies and their fragments, has not been demonstrated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intranasal Administration of Active Agents to the Central Nervous System
  • Intranasal Administration of Active Agents to the Central Nervous System
  • Intranasal Administration of Active Agents to the Central Nervous System

Examples

Experimental program
Comparison scheme
Effect test

example 1

Brain Distribution of α-Melanocyte Stimulating Hormone Mimetibody after Intranasal Administration

[0133]This example shows that an α-melanocyte stimulating hormone mimetibody (α-MSH mimetibody) is transported to various regions in the brain and was detected at about 25 minutes after intranasal administration while reducing systemic exposure according to the methods of the present invention. The example further shows that the α-MSH mimetibody delivered to the brain is retained in the brain for at least up to 5 hours post-delivery.

Methods

[0134]An α-MSH mimetibody was prepared, to serve as a model and exemplary therapeutic compound to illustrate the claimed method. The α-MSH mimetibody is a homo-dimeric fusion molecule that consists of the therapeutic α-MSH polypeptide, identified herein as SEQ ID NO:1, and the Fc portion of the human immunoglobulin G1 (IgG1) monoclonal antibody. The engineered fusion polypeptide was produced using recombinant DNA methods.

[0135]The α-MSH mimetibody was ...

example 2

Dose-Dependent Reduction in Cumulative Food Intake in Normal Rats after Intranasal Administration of Alpha-MSH

[0144]This example shows that intranasal administration of a single dose of the N-acetylated α-melanocyte stimulating hormone (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, SEQ ID NO:1, supplied by Phoenix Pharmaceuticals, INC) was sufficient to achieve a dose dependent, pharmacodynamic response; specifically, a reduction of cumulative food intake, with an ED50 at 24 hours of 6-7 nmol.

Methods

[0145]Two groups of nine rats each were assembled. In a cross-over design, each week one group was dosed with a phosphate buffered saline (PBS) vehicle and the other group was dosed with α-MSH peptide; the following week the treatment administered to each group was reversed. Prior to the study, the light cycle was slowly reversed, within a 2 weeks acclimation period. Rats were fasted for 24 hours prior to each experiment (water was always available), and received anesthesia...

example 3

Reduction in Cumulative Food Intake in Normal Rats after Intranasal Administration of Alpha-MSH Mimetibody

[0148]This example shows that intranasal administration of a single dose of 25 nmols (5 mg / kg) of the α-MSH mimetibody is sufficient to reduce cumulative food intake significantly at 8 and 24 hours. Water consumption and body weight remained unchanged.

Methods

[0149]The study protocol and methods used were the same as described in Example 2. The total number of rats was 14.

Results and Conclusions

[0150]As seen in FIG. 7, a single dose of 25 nmol of intranasally delivered alpha-MSH mimetibody had a significant effect on decreasing cumulative food intake at 8 and 24 hours, with a non-statistically significant trend toward reduction at 48 and 72 hours. The significance at the later time points was likely lost due to the relatively small number of animals used in the study (n=14). The study shows that a 62 kDa large protein, like the α-MSH mimetibody, can be delivered to the CNS via th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
timeaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 655,809, filed Feb. 23, 2005 and U.S. Utility application Ser. No. 11 / 342,058 filed Jan. 1, 2006, both of which are incorporated herein by reference in their entirety.TECHNICAL FIELD[0002]The subject matter described herein relates to methods and compositions for intranasal administration of active agents to the central nervous system of a mammal.BACKGROUND[0003]Delivery of drugs to the central nervous system (CNS) remains a challenge, despite recent advances in drug delivery and knowledge of mechanisms of delivery of drugs to the brain. For example, CNS targets are poorly accessible from the peripheral circulation due to the blood-brain barrier (BBB), which provides an efficient barrier for the diffusion of most, especially polar, drugs into the brain from the circulating blood. Attempts to circumvent the problems associated with the BBB to deliver drugs to the CN...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K38/43
CPCA61K51/086C07K2319/30A61K47/48415A61K51/088A61K47/34A61K38/34A61K47/26A61K9/0043A61K38/50A61K47/28A61K47/6811A61P1/14A61P21/00A61P21/04A61P25/00A61P25/08A61P25/14A61P25/16A61P25/20A61P25/28A61P3/00A61P3/04A61P37/06A61P43/00A61P9/00A61P3/10A61K47/6851C07K14/685C07K16/18
Inventor BENTZ, JOHANNAHILL, BETHILLUM, LISBETH
Owner BENTZ JOHANNA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com